Skip to main content

Advertisement

SpringerLink
Log in

Non-AIDS-defining Cancers Among HIV-Infected Patients

  • Metabolic Complications and Comorbidity (JM Kilby, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

In the highly active antiretroviral therapy (HAART) era, the incidence of non-AIDS-defining cancers (NADC) has increased and contributes to a growing proportion of mortality in the aging HIV-infected population. The underlying pathogenic mechanisms of increased cancer risk are incompletely understood. Potential contributors include oncogenic effects of the HIV virus, immunosuppression, chronic inflammation and immune activation, exposure to HAART, higher rates of oncogenic viral coinfections and traditional cancer risk factors. HIV-infected patients often present with NADC at younger ages with more aggressive or advanced stage disease. However, when standard cancer therapy is given, treatment outcomes appear similar to the non-HIV population. These facts highlight the importance of clinicians’ maintaining a high index of suspicion, performing age-appropriate screening, and optimizing cancer therapy. Development of novel strategies for screening, prevention, and treatment of NADC will be required to reverse these epidemiologic trends and improve the survival of HIV-infected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590–8.

    Article  PubMed  Google Scholar 

  2. Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.

    Article  PubMed  CAS  Google Scholar 

  3. Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008. MMWR Recomm Rep. 2008;57:1–12.

    PubMed  Google Scholar 

  4. •• Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62. This study provides U.S. national estimates of annual cancer burden by calculating incident cancers, by cancer type, from 1991 to 2005 in HIV-infected patients with and without AIDS. A dramatic shift in the spectrum of cancers from ADC to NADC occurred, driven by aging and growth of the HIV population.

    Article  PubMed  Google Scholar 

  5. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94.

    Article  PubMed  CAS  Google Scholar 

  6. Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55:1228–35.

    Article  PubMed  Google Scholar 

  7. • Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis. 2010;51:957–62. This study described cancer-related mortality in a US registry-based cohort of 83,282 AIDS patients from 1980 to 2006. Significant decreases in mortality from ADC and NADC occurred during the HAART era, but due to faster declines in mortality from other AIDS-related deaths, the proportion of deaths from cancers increased, particularly from NHL and lung cancers.

    Article  PubMed  Google Scholar 

  8. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203–8.

    Article  PubMed  Google Scholar 

  9. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611–22.

    Article  PubMed  Google Scholar 

  10. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS. 2009;23:875–85.

    Article  PubMed  Google Scholar 

  11. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23:2337–45.

    Article  PubMed  Google Scholar 

  12. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36.

    Article  PubMed  Google Scholar 

  13. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41–50.

    Article  PubMed  Google Scholar 

  14. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884–90.

    Article  PubMed  Google Scholar 

  15. • Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22. This update from the Swiss HIV Cohort Study reports SIRs and age-standardized cancer incidence comparing 9429 HIV-infected patients to controls from Swiss cantonal cancer registries in the pre-, early-, and late-HAART periods. Increases in the incidence of select NADC occurred in the early-HAART era, but overall NADC incidence was double that of the general population and remained stable in all periods.

    Article  PubMed  CAS  Google Scholar 

  16. • Dubrow R, Silverberg MJ, Park LS, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012;24:506–16. This recent review explores in detail the relationship of immunodeficiency, chronic inflammation, and immune activation to cancer risk in HIV-infected patients. The authors also summarize the existing data regarding the relationship of CD4 count to overall NADC rates and specific cancer types, discussing possible explanations for discrepant findings.

    Article  PubMed  CAS  Google Scholar 

  17. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397–406.

    Article  PubMed  Google Scholar 

  18. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.

    Article  PubMed  CAS  Google Scholar 

  19. Persson EC, Shiels MS, Dawsey SM, et al. Increased risk of stomach and esophageal malignancies in people with AIDS. Gastroenterology. 2012;143:943–50. e942.

    Article  PubMed  Google Scholar 

  20. Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105:350–60.

    Article  PubMed  CAS  Google Scholar 

  21. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104:1505–11.

    Article  PubMed  Google Scholar 

  22. Suneja G, Shiels MS, Melville SK, et al. Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. AIDS. 2013;27:459–68.

    Article  PubMed  Google Scholar 

  23. Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527–37.

    Article  PubMed  Google Scholar 

  24. Goedert JJ, Schairer C, McNeel TS, et al. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer. 2006;95:642–8.

    Article  PubMed  CAS  Google Scholar 

  25. Levine AM, Seaberg EC, Hessol NA, et al. HIV as a risk factor for lung cancer in women: data from the Women’s Interagency HIV Study. J Clin Oncol. 2010;28:1514–9.

    Article  PubMed  Google Scholar 

  26. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54:1026–34.

    Article  PubMed  Google Scholar 

  27. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–32.

    Article  PubMed  Google Scholar 

  28. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527–33.

    Article  PubMed  Google Scholar 

  29. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109–16.

    Article  PubMed  Google Scholar 

  30. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152–9.

    Article  PubMed  CAS  Google Scholar 

  31. Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis. 2010;50:1316–21.

    Article  PubMed  CAS  Google Scholar 

  32. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116:5306–15.

    Article  PubMed  Google Scholar 

  33. Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458–65.

    Article  PubMed  CAS  Google Scholar 

  34. Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011;80:42–9.

    Article  PubMed  Google Scholar 

  35. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989–2002. Clin Infect Dis. 2004;39:1380–4.

    Article  PubMed  Google Scholar 

  36. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22:2143–53.

    Article  PubMed  Google Scholar 

  37. •• Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9. This study from the Kaiser Permanente HIV cohort compared cancer risk in 20,775 HIV-infected patients and 215,158 HIV-infected controls from the same healthcare system. After adjustment for demographic and traditional cancer risk factors, elevated RRs were seen for 7 of 10 cancer types studied and an association of lower CD4 count, and elevated risk was seen for 9 of 10 cancer types studied.

    Article  PubMed  CAS  Google Scholar 

  38. Harrod R, Nacsa J, Van Lint C, et al. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem. 2003;278:12310–8.

    Article  PubMed  CAS  Google Scholar 

  39. De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene. 2003;22:6214–9.

    Article  PubMed  Google Scholar 

  40. Wright S, Lu X, Peterlin BM. Human immunodeficiency virus type 1 tat directs transcription through attenuation sites within the mouse c-myc gene. J Mol Biol. 1994;243:568–73.

    Article  PubMed  CAS  Google Scholar 

  41. Campioni D, Corallini A, Zauli G, et al. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Hum Retroviruses. 1995;11:1039–48.

    Article  PubMed  CAS  Google Scholar 

  42. Colombrino E, Rossi E, Ballon G, et al. Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res. 2004;295:539–48.

    Article  PubMed  CAS  Google Scholar 

  43. Nyagol J, Leucci E, Onnis A, et al. The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther. 2006;5:684–90.

    Article  PubMed  CAS  Google Scholar 

  44. Altavilla G, Caputo A, Lanfredi M, et al. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am J Pathol. 2000;157:1081–9.

    Article  PubMed  CAS  Google Scholar 

  45. Corallini A, Campioni D, Rossi C, et al. Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS. 1996;10:701–10.

    Article  PubMed  CAS  Google Scholar 

  46. Wistuba II, Behrens C, Milchgrub S, et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA. 1998;279:1554–9.

    Article  PubMed  CAS  Google Scholar 

  47. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285–93.

    Article  PubMed  Google Scholar 

  48. McGinnis KA, Fultz SL, Skanderson M, et al. Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006;24:5005–9.

    Article  PubMed  Google Scholar 

  49. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4:52–6.

    Article  PubMed  Google Scholar 

  50. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–9.

    Article  PubMed  Google Scholar 

  51. Ahdieh L, Munoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol. 2000;151:1148–57.

    Article  PubMed  CAS  Google Scholar 

  52. Kato T, Koriyama C, Khan N, et al. EGFR mutations and human papillomavirus in lung cancer. Lung Cancer. 2012;78:144–7.

    Article  PubMed  Google Scholar 

  53. Syrjanen K. Detection of human papillomavirus in lung cancer: systematic review and meta-analysis. Anticancer Res. 2012;32:3235–50.

    PubMed  Google Scholar 

  54. Thompson LD, Fisher SI, Chu WS, et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121:727–38.

    Article  PubMed  Google Scholar 

  55. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS. 2009;4:3–10.

    Article  PubMed  Google Scholar 

  56. Wieland U, Kreuter A. Merkel cell polyomavirus infection and Merkel cell carcinoma in HIV-positive individuals. Curr Opin Oncol. 2011;23:488–93.

    Article  PubMed  Google Scholar 

  57. Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 2003;5:172–7.

    PubMed  Google Scholar 

  58. Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400–6.

    PubMed  CAS  Google Scholar 

  59. Schacker TW, Nguyen PL, Martinez E, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis. 2002;186:1092–7.

    Article  PubMed  Google Scholar 

  60. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.

    Article  PubMed  Google Scholar 

  61. Plaeger SF, Collins BS, Musib R, et al. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses. 2012;28:469–77.

    PubMed  CAS  Google Scholar 

  62. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011;103:1112–22.

    Article  PubMed  CAS  Google Scholar 

  63. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.

    Article  PubMed  Google Scholar 

  64. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201:1796–805.

    Article  PubMed  CAS  Google Scholar 

  65. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep. 2012;9:223–30.

    Article  PubMed  Google Scholar 

  66. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010;100:1896–903.

    Article  PubMed  Google Scholar 

  67. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24:1383–8.

    Article  PubMed  Google Scholar 

  68. Kirk GD, Merlo C, O’ Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103–10.

    Article  PubMed  Google Scholar 

  69. Olivero OA, Tejera AM, Fernandez JJ, et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005;20:139–46.

    Article  PubMed  CAS  Google Scholar 

  70. Carter MM, Torres SM, Cook Jr DL, et al. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen. 2007;48:239–47.

    Article  PubMed  CAS  Google Scholar 

  71. Crum-Cianflone NF, Hullsiek KH, Marconi V, et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2009;51:305–9.

    Article  PubMed  CAS  Google Scholar 

  72. Yopp AC, Subramanian M, Jain MK, et al. Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol. 2012;10:1284–90.

    Article  PubMed  Google Scholar 

  73. Wilkins K, Turner R, Dolev JC, et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54:189–206. quiz 207–110.

    Article  PubMed  Google Scholar 

  74. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002;138:758–63.

    Article  PubMed  Google Scholar 

  75. • Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26:1017–25. This Veterans Aging Cohort Study compared lung cancer incidence in demographically similar HIV-infected and uninfected veterans. After controlling for smoking, HIV remained an independent risk factor for lung cancer in one of the largest studies to directly examine the contributions of HIV and smoking to lung cancer risk.

    Article  PubMed  Google Scholar 

  76. D’Jaen GA, Pantanowitz L, Bower M, et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer. 2010;11:396–404.

    Article  PubMed  Google Scholar 

  77. Gewurz BE, Dezube BJ, Pantanowitz L. HIV and the breast. AIDS Read. 2005;15(392–396):399–402.

    Google Scholar 

  78. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer. 2009;8:215–9.

    Article  PubMed  Google Scholar 

  79. Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293–9.

    Article  PubMed  Google Scholar 

  80. Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J Acquir Immune Defic Syndr. 2010;55:510–5.

    Article  PubMed  Google Scholar 

  81. • Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111–6. This trial reported on 93 HIV-infected and 131 HIV-uninfected patients with HL treated with aggressive combination chemotherapy from 1997 to 2010. Despite more extensive disease and adverse prognostic factors, HIV-infected patients had similar five-year overall and event-free survival to HIV-negative patients.

    Article  PubMed  Google Scholar 

  82. Abramowitz L, Mathieu N, Roudot-Thoraval F, et al. Epidermoid anal cancer prognosis comparison among HIV + and HIV- patients. Aliment Pharmacol Ther. 2009;30:414–21.

    Article  PubMed  CAS  Google Scholar 

  83. Lim C, Goutte N, Gervais A, et al. Standardized care management ensures similar survival rates in HIV-positive and HIV-negative patients with hepatocellular carcinoma. J Acquir Immune Defic Syndr. 2012;61:581–7.

    Article  PubMed  Google Scholar 

  84. Powles T, Thirwell C, Newsom-Davis T, et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer. 2003;89:457–9.

    Article  PubMed  CAS  Google Scholar 

  85. Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS. 2002;16:531–6.

    Article  PubMed  CAS  Google Scholar 

  86. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol. 2009;21:445–54.

    Article  PubMed  CAS  Google Scholar 

  87. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027–32.

    Article  PubMed  Google Scholar 

  88. European AIDS Clinical Society: Cancer Screening Methods. Available at http://www.europeanaidsclinicalsociety.org/Guidelines/G2_p37.htm. Accessed March 2013.

  89. New York State Health Department: Adult HIV Clinical Guidelines. Available at http://www.hivguidelines.org/clinical-guidelines/adults. Accessed March 2013.

  90. • Sigel K, Dubrow R, Silverberg M, et al. Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep. 2011;8:142–52. This recent article reviews existing evidence for cancer screening in HIV-infected patients. A paradigm for approaches to cancer screening is proposed and key research questions are identified, including the need for HIV-specific cancer screening guidelines.

    Article  PubMed  Google Scholar 

  91. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.

    Article  PubMed  Google Scholar 

  92. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822–9.

    Article  PubMed  CAS  Google Scholar 

  93. Lam JM, Hoch JS, Tinmouth J, et al. Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS. 2011;25:635–42.

    Article  PubMed  Google Scholar 

  94. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009; 58:68–91.

    Google Scholar 

  95. Reinhold JP, Moon M, Tenner CT, et al. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol. 2005;100:1805–12.

    Article  PubMed  Google Scholar 

  96. • Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727–34. This study using the Danish nationwide HIV cohort and matched HIV-negative controls estimated mortality rates and population-attributable risk of death associated with smoking. The results suggested that HIV-infected smokers on HAART lose more life-years from smoking than HIV and have twice the population-attributable risk of death associated with smoking compared to controls.

    Article  PubMed  Google Scholar 

  97. Recommended adult immunization schedule: United States, 2012. Ann Intern Med. 2012; 156:211–217.

  98. Drechsler H, Zhang S, Maalouf N, et al. Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART. [abstract R-260]. Presented at the 20th Conference for Retroviruses and Opportunistic Infections. Atlanta, GA; March 3–6, 2013.

  99. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013. doi:10.1093/cid/cit053.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

James Cutrell declares that he has no conflict of interest.

Roger Bedimo is a Scientific Advisory Board consultant for Abbott.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, 5323 Harry Hines Blvd., Dallas, TX, 75390-9113, USA

    James Cutrell

  2. Infectious Diseases Section, VA North Texas Health Care System, Dallas, Texas, 4500 S. Lancaster Road 111-D, Dallas, TX, 75216, USA

    Roger Bedimo

  3. Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, 4500 S. Lancaster Road 111-D, Dallas, TX, 75216, USA

    Roger Bedimo

Authors
  1. James Cutrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger Bedimo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Bedimo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cutrell, J., Bedimo, R. Non-AIDS-defining Cancers Among HIV-Infected Patients. Curr HIV/AIDS Rep 10, 207–216 (2013). https://doi.org/10.1007/s11904-013-0166-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-013-0166-8

Keywords

Search

Navigation